Patents by Inventor Takashi Uwano

Takashi Uwano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human lung adenocarcinoma-related monoclonal antibody and antigen and immunaossay method which uses the same
    Publication number: 20050238652
    Abstract: The monoclonal antibody produced by a hybridoma cell strain TRD-L1, -L2 or -L3 which is obtained by the fusion between mouse myeloma cells and spleen cells of a mouse immunized with a human lung adenocarcinoma cell secretion component reacts in a specific fashion with a glycoprotein antigen that has a molecular weight of 200 kD or more (SDS-PAGE) and is present in human lung adenocarcinoma cells. It can be used efficiently in cancer diagnosis.
    Type: Application
    Filed: June 24, 2005
    Publication date: October 27, 2005
    Applicant: Fujirebio Inc.
    Inventors: Kouichi Tsuji, Yoshihiro Yoshida, Takashi Uwano
  • Human lung adenocarcinoma-related monoclonal antibody and antigen and immunoassay method which uses the same
    Patent number: 6919435
    Abstract: The monoclonal antibody produced by a hybridoma cell strain TRD-L1, -L2 or -L3 which is obtained by the fusion between mouse myeloma cells and spleen cells of a mouse immunized with a human lung adenocarcinoma cell secretion component reacts in a specific fashion with a glycoprotein antigen that has a moecular weight of 200 kD or more (SDS-PAGE) and is present in human lung adenocarcinoma cells. It can be used efficiently in cancer diagnosis.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: July 19, 2005
    Assignee: Fujirebio Inc.
    Inventors: Kouichi Tsuji, Yoshihiro Yoshida, Takashi Uwano
  • Human lung adenocarcinoma-related monoclonal antibody and immunoassay method which uses the same
    Patent number: 6015680
    Abstract: The monoclonal antibody produced by a hybridoma cell strain TRD-L1, -L2 or -L3 which is obtained by the fusion between mouse myeloma cells and spleen cells of a mouse immunized with a human lung adenocarcinoma cell secretion component reacts in a specific fashion with a glycoprotein antigen that has a molecular weight of 200 kD or more (SDS-PAGE) and is present in human lung adenocarcinoma cells. It can be used efficiently in cancer diagnosis.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: January 18, 2000
    Assignee: Terumo Kabushiki Kaisha
    Inventors: Kouichi Tsuji, Yoshihiro Yoshida, Takashi Uwano